Am J Health Syst Pharm. 2010;67(24):2095-2106. The second mTOR complex, mTORC2, contains mTOR, mLST8, and several unique proteins, including rictor (rapamycin-insensitive companion of mTOR). Rapamycin ...
Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved ...
Palvella plans to submit a New Drug Application to the Food and Drug Administration in the second half of 2026. Topline data were announced from a phase 3 trial evaluating QTORIN ™ 3.9% rapamycin ...
Although it’s true that average life expectancy is increasing, this increase is not driven by healthy years lived. Instead, it’s mostly driven by an increase in unhealthy years lived. As the disease ...
Palvella Therapeutics reports progress in clinical trials for QTORIN™ rapamycin, exceeding patient enrollment and anticipating significant results in upcoming years. Net loss of $8.2 million for the ...
Studies in yeast, flies and mice have shown that relatively low doses of rapamycin often increase the creatures’ lifespans.
Worldwide obesity rates have more than doubled since 1990, with nearly a billion people now falling into the category. Though a complex interplay of genes, diet, and environment contribute, 90% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results